TGFB2 and Cirrhosis: Moreover, the differential expression of TGFB2/TGFB2 OT1 in advanced fibrosis/cirrhosis and absent or mild-to-moderate fibrosis patients was also confirmed in an external validation cohort of 50 NAFLD patients, and it yielded a high predictive capability for subjects with advanced fibrosis (AUC = 0.797 and 0.786 in internal and external cohorts, respectively), with sensitivity values of 65% and 62.5%, and specificity values of 81.3% and 94.4% in internal and external cohorts, respectively [43].